Celgene fends off Kyle Bass challenge

Biopharmaceutical company Celgene has finally found success in fending off a challenge to one of its patents fr om Kyle Bass’s organisation the Coalition for Affordable Drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB accepts Bass’s toenail patent challenges

25 February 2016 The Coalition for Affordable Drugs and Anacor Pharmaceuticals will face off in a dispute over the validity of two anti-fungal patents after the Patent Trial and Appeal Board gave the go-ahead to two inter partes review petitions.

Americas

Bass returns funds but vows to continue pharma fight

24 February 2016 Hedge fund manager Kyle Bass has returned almost $700 million to investors that backed his inter partes review challenges, but has vowed to continue challenging pharmaceutical patents after being given the green light to tackle another.

Americas

PTAB grants IPR of Celgene patents after Kyle Bass challenge

28 October 2015 The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene.